Enliven Therapeutics Director Sells $345,000 Worth of Shares Amid Stock Surge
Lori Anne Kunkel, a director at Enliven Therapeutics (ELVN), sold 10,000 shares for approximately $345,000 on June 5, 2026. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan and marked Kunkel's first open-market sale of the company’s stock.
Tickers: $ELVN